OverviewChartNewsTraderScreen

Morgan Stanley Call 80 SNW 20.09..../  DE000ME2BJH9  /

Stuttgart
17/07/2024  21:13:51 Chg.-0.08 Bid22:00:35 Ask22:00:35 Underlying Strike price Expiration date Option type
7.96EUR -1.00% -
Bid Size: -		 -
Ask Size: -		 SANOFI SA INHABER ... 80.00 EUR 20/09/2024 Call
GlobeNewswire 28/06 Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Di...
TeleTrader 27/06 Europe opens mixed before consumer confidence data
GlobeNewswire 27/06 Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
GlobeNewswire 26/06 Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...
GlobeNewswire 26/06 Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic e...
GlobeNewswire 21/06 Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s ...
GlobeNewswire 21/06 Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusi...
GlobeNewswire 20/06 Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
GlobeNewswire 18/06 Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Sm...
GlobeNewswire 11/06 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire 03/06 Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival ...
GlobeNewswire 31/05 Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
GlobeNewswire 31/05 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire 31/05 Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire 31/05 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire 31/05 Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire 30/05 Press Release: Sanofi completes acquisition of Inhibrx, Inc.
GlobeNewswire 27/05 Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire 23/05 CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
GlobeNewswire 21/05 Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire 20/05 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire 20/05 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire 20/05 Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire 13/05 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire 13/05 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...